BioSpace News Archive

Drug Development

Senti Bio Highlights Colorectal Cancer Preclinical Data from Logic Gated CAR-NK Cell Program at 36th SITC Annual Meeting

Senti Bio, a leading gene circuit company, today announced results from SENTI-401, one of its preclinical stage oncology programs, that aims to more precisely target tumors while sparing healthy cells.

November 12, 2021
·
4 min read
FDA

FDA Approves Treatment for Rare Blood Disease

Today, the U.S. Food and Drug Administration approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera, a blood disease that causes the overproduction of red blood cells.

November 12, 2021
·
3 min read
Drug Development

Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting

Moderna, Inc., (Nasdaq: MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced interim data from an ongoing Phase 1 clinical study of mRNA-2752 (Triplet) in patients with accessible solid tumors and lymphomas.

November 12, 2021
·
6 min read
Acasti Pharma Announces Annual Stock Option Grants - Nov 12, 2021

Acasti Pharma Inc., announced the annual grant of stock options to its employees, executives and directors.

November 12, 2021
·
5 min read
Business

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer

Appili Therapeutics Inc., a biopharmaceutical company developing anti-infective drug candidates, announced its financial and operational results for the second quarter of its fiscal year 2022, which ended on September 30, 2021.

November 12, 2021
·
6 min read
Business

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced certain financial and operational results for the quarter ended September 30, 2021.

November 12, 2021
·
7 min read
FDA

U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera

PharmaEssentia Corporation (TPEx: 6446), today announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera (PV).

November 12, 2021
·
16 min read